Endoscopic Lung Volume Reduction
An American Perspective

Hans J. Lee*, Samira Shojaee*, and Daniel H. Sterman

Background:
Severe emphysema is an important problem, affecting ~10% of people in the USA and is the fourth leading cause of death\(^1\). Treatment options include smoking cessation, inhaled medications, systemic steroids, pulmonary rehabilitation, supplemental oxygen and lung transplantation. Lung volume reduction surgery (LVRS) “reduction pneumoplasty” was first described in 1957 by Otto Brantigan\(^2\) and was later reintroduced and refined by Joel Cooper\(^3\). In the 1990s the National Institute of Health (NIH) launched a trial of medical therapy vs. surgical treatment using lung volume reduction to see if these patients would have an alternative strategy to treat this progressive disease. The goal of lung volume reduction is to remove emphysematous lung to improve hyperinflation, diaphragmatic mobility and expiratory flow. This trial was named the National Emphysema Treatment Trial (NETT) and results were published in 2003 which showed that a subset of patients who had upper lobe predominant emphysema and low baseline exercise capacity did benefit from LVRS and others did not\(^4\). A further study following patients undergoing LVRS noted a significant 90-day mortality rate in experienced hands (4%) and post-procedural morbidity; 46% with persistent air leak requiring intercostal drainage for > 7 days, 11% of patients with pneumonia, 7% of patients requiring intubation and 6% requiring further surgery\(^5\). Based on these results, there has been interest in development of a minimally-invasive way to reduce lung volume which can minimize morbidity and mortality. Several bronchoscopic modalities are being tested and considered for FDA approval. This article reviews all of these bronchoscopic lung volume reduction options.

Methods:
Design: Systematic review
Included Studies: Human studies, Prospective trials
Excluded Studies: Retrospective studies, Studies with < 20 subjects, early reports if the subjects were later used in a larger cohort/trial, Non-English publications
Search terms used: “bronchoscopic lung volume reduction” or “bronchoscopy emphysema treatment” or “bronchoscopy valves” or “bronchoscopy coils” or “bronchoscopy glue” or “bronchoscopy vapor.”
Databases searched: Cochrane Review, MEDLINE
Time period: Inception of database to September 2012

Results:
Valves:
The most studied of all endobronchial lung volume reduction techniques
- Reduce airflow into treated lobe during inhalation but allow air and secretions to be expelled during exhalation
- Patients who develop radiographic atelectasis show greatest benefits, those without have variable improvements.
- Improves: FEV\(_1\), lung volumes, 6 minute walk distance, health-related quality of life, St. George’s Respiratory Questionnaire (SGRQ)
- Advantage: easily reversible
- Use: heterogeneous, upper-lobe predominant emphysema without collateral ventilation
- 2 types:
  - **Spiration Intrabronchial valve**: Umbrella-shaped device with a nitinol frame consisting 5 distal anchors and 5 proximal struts with a central rod covered in a thin layer of polyurethane.
  - **Zephyr valve**: Duck-bill shaped, silicone-covered one way valve within a self-expanding stent that contains a flexible retainer which expands to anchor it to the airway and ensure an airtight seal.

**Biologic Lung volume reduction system:**
- Fibrinogen suspension and thrombin solution, which polymerize to a hydrogel as they come in contact with one another
- Induces a localized inflammatory reaction that causes atelectasis by occlusion and remodeling over 4- to 6-weeks.
- Improves FEV₁, FVC, RV/TLC, RV, dyspnea scores and SGRQ
- Can be used in homogeneous disease, is not affected by collateral ventilation
- Irreversible

**AeriSeal:**
- A synthetic version of biologic lung volume reduction system
- No human blood products are used which decreases risk of transmissible diseases
- Initially uses a primer to remove surfactant which causes atelectasis and then the synthetic hydrogel is introduced which causes inflammation resulting in scarring and remodeling over several weeks
- Improves FEV₁, RV and SGRQ
- Has been studied in upper lobe predominant disease
- Is not affected by collateral ventilation
- Irreversible

**Bronchoscopic thermal vapor ablation:**
- Use of heated water to produce thermal injury creating a localized inflammatory response followed by permanent fibrosis and atelectasis.
- Studied in heterogeneous, upper-lobe predominant disease
- Improves FEV₁, RV, 6-minute walk distance, BODE index, SGRQ
- Not affected by collateral ventilation
- Irreversible

**Coils:**
- Catheter loaded straightened nitinol coil over a guidewire. On coil deployment the straightened coil then conforms to its predetermined shape
- Coil deployment bends the airway resulting in compression of adjacent lung tissue
- Creates local lung volume reduction and restores elastic recoil of the healthier lung compartments.
- Improves SGRQ, FEV₁, RV and 6 minute walk distance
- Not affected by collateral ventilation
- Unclear if it can be reversed

**Airway bypass:**
- Initially created to treat homogeneous disease
Placement of drug-eluting stent-supported fenestrations in the airway wall to allow for decrease in air trapping and an increased volume of air expelled during forced exhalations

Was not successful: improvements were transient, the procedure is technically difficult and the stents are easily displaced or obstructed

Commentary:

This is a thorough review outlining all of the prospective data for the various endoscopic lung volume reduction strategies (ELVR), all in one place which makes it easy to compare one methodology to another. None of these modalities are available in the USA as they have not yet been approved by the Food and Drug Administration (FDA) but clinical trials are underway. Currently, intrabronchial valves are approved only for humanitarian device exemption for persistent air leaks following segmentectomy, lobectomy and lung volume reduction surgery.

Interestingly, in the same publication of Annals of the ATS, the counterpart article from the European perspective was also published. In Europe, all of the above techniques for ELVR have been approved and are in use. Hopefully, we will have more data obtained from a larger cohort that is a more generalizable population of patients with severe COPD demonstrating benefit.

ELVR strategies include devices that completely occlude an airway causing lobar collapse, those that mechanically decrease the lung volume and mechanisms that induce inflammation and cause subsequent fibrosis thereby decreasing lung volume. Initially, complete bilateral upper lobe treatment was attempted, but this led to pneumothoraces. Additionally, some patients were noted to have benefit without lobar collapse. This effect was postulated to be secondary to improvements in dynamic hyperinflation, collateral ventilation, ventilation/perfusion matching and redirection of ventilation to more functional alveolar units. The variables used to predict which form of bronchoscopic treatment would be most beneficial include collateral ventilation and disease heterogeneity. These characteristics are important as data suggest that indiscriminate use of ELVR strategies for patients with severe emphysema leads to clinically insignificant benefits.

Collateral ventilation was first described by Van Allen et al. in 1931 and is defined as alveolar ventilation via channels that bypass the usual airways. This phenomenon is negligible in normal lung but is present in two thirds of patients with severe emphysema. Physiologically, the resistance to air flow in the bronchioles is increased by mucous in patients with COPD. Increased airway resistance is then compounded by exaggerated expiratory collapse which eventually exceeds the resistance in the collateral airways thereby making them functional.

The importance of collateral ventilation was noted during the first randomized control trial comparing medical therapy to endobronchial valve placement called the Endobronchial Valve for Emphysema Palliation Trial (VENT). An observation made during subgroup analysis of the European cohort of the VENT trial (Euro-VENT) was that the presence of a complete interlobar fissure on CT scan was an independent predictor of treatment response. When there is a defect in the interlobar fissure, ventilation takes place through the pores of Kohn which are typically only used for movement of respiratory cells such as macrophages and surfactant. Collateral ventilation is thought to derive more commonly from channels of Lambert which represent epithelium-lined tubular communications between distal bronchioles and adjacent alveoli as well as the pathways of Martin which are accessory communications between terminal bronchioles from adjacent lung segments allowing for lobar ventilation despite airway occlusion. These airflow connections therefore can occur in both interlobular as well as interlobar areas.

In order to evaluate a patient for collateral ventilation, high resolution CT scan (HRCT) analysis of the “completeness” of the interlobar fissures has become a surrogate measure. A cutoff of 90% completeness in 1 plane on high resolution CT is used to describe a complete fissure. Anything less is considered incomplete. In a study by Aziz et al. 622 subjects with either no lung disease, or mild lung disease thought not to involve the fissures were enrolled and interlobar fissure completeness was precisely analyzed using HRCT. As a follow-up to this information, another study of 96 patients with severe emphysema had a CT scan and an automated method was applied to quantify fissure completeness.
completeness. Based on this analysis, emphysema was shown not to significantly affect fissure completeness by CT scan\textsuperscript{12}.

To evaluate the consistency of evaluation of high resolution CT scan for fissural integrity, CT scans of 35 patients were retrospectively reviewed by 2 pulmonologists, 1 general radiologist and 2 experienced chest radiologists, independently and blinded for treatment outcome. The pulmonary fissures were classified as either complete or incomplete. Inter-observer agreement was then assessed. They found that pulmonologists and radiologists agreed fairly well in fissure analysis, while the experienced chest radiologists reached the highest clinically adequate agreement\textsuperscript{13}.

Given these challenges, a more objective, catheter-based measurement was developed to assess collateral ventilation as a reliable predictor of endobronchial valve success or failure. The system is called Chartis\textsuperscript{™}. The Chartis\textsuperscript{™} system consists of two compartments: a catheter and a console. Measurements are performed during bronchoscopy using a catheter placed in the airway of the target lung lobe. A balloon situated at the tip of the catheter allows for isolation of an area of lung. Air flow and pressure are measured and resistance of collateral channels can be calculated. A gradual decline in expiratory flow after balloon occlusion suggests that there is an absence of collateral ventilation whereas the persistence of flow after 5 min of balloon inflation suggests significant collateral ventilation.

The value of the Chartis\textsuperscript{™} system has been studied prospectively in a multicenter trial in Europe\textsuperscript{7, 13, 14, 15}. Patients were classified into two groups according to the presence or absence of collateral ventilation in the lobe of interest as determined by the Chartis\textsuperscript{™} system and then an endobronchial valve was placed. There was a much greater volume reduction and mean percentage increase in FEV\textsubscript{1} in the group without collateral ventilation as opposed to those found to have collateral ventilation. In a subgroup from this case series the patients were also evaluated for integrity of the lobar fissure. The accuracy in predicting a responder was similar irrespective of the method used to classify collateral ventilation status. Of note, the Chartis\textsuperscript{™} system is sometimes technically difficult because of low patient tolerance (coughing), incorrect positioning of the catheter secondary to difficult anatomy, or the presence of mucous which can block the catheter\textsuperscript{14}. The Chartis\textsuperscript{™} system is currently approved for clinical use in Europe but is not yet available in the United States other than for research purposes.

It has been suggested that collateral ventilation occurs to a greater extent in homogeneous emphysema than in heterogeneous disease which can explain why patients with upper lobe predominant disease fare better with ELVR in general\textsuperscript{16}. Additionally, a high heterogeneity index (HI) was predictive of successful lung volume reduction.

The HI is measured as the ratio of destruction between the target area for bronchoscopic lung volume reduction and another ipsilateral lobe. Patients with a higher HI show greater benefit with lung volume reduction than do patients with a lower HI. A cutoff value of 15\% is arbitrarily used to describe patients with high heterogeneity. The HI is important as patients with an elevated HI have evidence of less-diseased lung on the ipsilateral side which will benefit from improved respiratory dynamics following atelectasis of the more damaged areas of lung. Despite this inherently intuitive explanation, we still have much to learn about the effects of homogeneous vs. heterogenous disease as studies on collateral ventilation have shown that patients without collateral ventilation still benefit significantly from lobar collapse despite having homogeneous disease. Therefore, patients with a low heterogeneity index should not unilaterally be excluded from lung volume reduction. HI can be determined either by interpretation of the CT scan of the chest by an experienced clinician, though this has been shown to have high inter-rater variability and therefore low reliability. Software is available now that offers more standardization and therefore more reliability to the results.

Finally, ELVR should only be used in patients with severe emphysema (FEV\textsubscript{1} 20-45\% and RV >150\%). The diagram below is an algorithm for bronchoscopic lung volume reduction in patients with severe emphysema.(Taken from Shah PL. and Herth FJF. Current status of bronchoscopic lung volume reduction with endobronchial valves. Thorax 2014;69:280–286)\textsuperscript{7}
This paper’s limitations include the exclusion of retrospective studies and reports of ELVR with less than 20 patients which may still provide valuable information.

Overall, this paper is an extremely helpful overview of ELVR for the Interventional Pulmonologist. ELVR appears to be safe and will hopefully become an attractive minimally-invasive alternative for patients with severe COPD. Although, ELVR remains experimental, emerging data is promising. Refining patient selection and measurements to best qualify and quantify improvement outcomes is the current challenge.

**Authors**

Christine Argento, MD, FCCP  
Assistant Professor of Medicine  
Interventional Pulmonology  
Emory University  

Matthew Kinsey M.D., M.P.H.  
Assistant Professor  
Division of Pulmonary and Critical Care  
University of Vermont College of Medicine  

Momen M. Wahidi, MD, MBA  
Director, Interventional Pulmonology and Bronchoscopy  
Associate Professor of Medicine  
Duke University Medical Center
References:


